TABLE 4.
TITE‐CRM | TITE‐CRM2 | ICSDP | POMM | nTTP | TITE‐BOIN | TITE‐mTPI2 | R‐mTPI2 | |
---|---|---|---|---|---|---|---|---|
Stopping reason | Scenario A | |||||||
Sufficient information | 99 | 100 | 100 | 97 | 100 | 95 | 100 | 99 |
Maximum patients | 2 | 1 | 2 | 3 | 0 | 10 | 1 | 1 |
Stopping reason | Scenario B | |||||||
Sufficient information | 90 | 88 | 95 | 95 | 96 | 80 | 95 | 75 |
Maximum patients | 21 | 22 | 11 | 5 | 4 | 41 | 11 | 32 |
Stopping reason | Scenario C | |||||||
Sufficient information | 100 | 100 | 100 | 96 | 100 | 95 | 100 | 100 |
Maximum patients | 1 | 0 | 1 | 4 | 0 | 8 | 1 | 1 |
Stopping reason | Scenario D | |||||||
Sufficient information | 89 | 94 | 100 | 99 | 96 | 99 | 99 | 99 |
Maximum patients | 32 | 16 | 2 | 1 | 4 | 2 | 2 | 5 |
Note: The sum of these may be greater than 100, since it is possible for more than one rule to be triggered in a single trial.